Allenex AB: Interim Report January - September 2013

Regulatory News:

Allenex AB (STO:ALNX):

For the third quarter, July-September

· Net sales for the quarter amounted to SEK 28.4 million (26.7). Sales were impacted by a positive currency effect of SEK 0.3 million compared to the same period last year.

· Operating income (EBIT) for the quarter was SEK 2.8 million (1.3), with currency effects having a negative impact of SEK 1.0 million compared to the same period last year.

· Operating margin for the quarter was 9 percent (4).

· Loss after tax for the quarter was SEK 0.3 million (-1.8).

· Earnings per share for the quarter, basic and diluted, were SEK 0.00 (-0.01).

For the January-September period

· Net sales for the period amounted to SEK 82.4 million (85.3). Sales were impacted by a negative currency effect of SEK 1.9 million compared to the same period last year.

· Operating income (EBIT) for the period was SEK 7.4 million (7.4), with currency effects having a negative impact of SEK 2.5 million compared to the same period last year.

· Operating margin for the period was 8 percent (8).

· Earnings after tax for the period were SEK 2.1 million (-0.6).

· Earnings per share for the period, basic and diluted, were SEK 0.03 (0.00).

Significant events in the third quarter

· Allenex XM-ONE® test is approved for sales in Mexico.

· Allenex appoints new Head of Olerup Inc. in the U.S.

Allenex president and CEO Anders Karlsson’s commentary on the third quarter 2013:

"It is good to see that sales of the SBT Resolver™ product line from our Australian partner Conexio Genomics have now taken off. During the third quarter, several new centers in the U.S. commenced clinical use of the product. Sales growth in our U.S. based sales company was a full 29 percent compared to the same period last year. We are also positive about the European market, where in the third quarter, despite the challenging business environment, we successfully met last year’s sales figures. Our geographic expansion of the Olerup SSP® product line continues and we are working actively to build up new distribution channels on growth markets.”

This information was brought to you by Cision http://news.cision.com